The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

Cancer

Volumn 118, Issue 4, 2012, Pages 899-907

  Kriege, Mieke ^a   Jager, Agnes ^a   Hooning, Maartje J ^a   Huijskens, Elisabeth ^a   Blom, Jannet ^a   Van Deurzen, Carolien H M ^a   Bontenbal, Marijke ^a   Collee, J Margriet ^a   Menke Pluijmers, Marian B E ^a   Martens, John W M ^a   Seynaeve, Caroline ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BRCA1; BRCA2; breast cancer; docetaxel; metastatic disease; paclitaxel

Indexed keywords

DOCETAXEL; HORMONE RECEPTOR; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BRCA2 ONCOGENE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; CANCER RECURRENCE; DISEASE ASSOCIATION; MAJOR CLINICAL STUDY; REPEATED DRUG DOSE; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; MIDDLE AGED; MUTATION; PHARMACOGENETICS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 83755168231     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26351     Document Type: Article

References (24)

1. Early breast cancer trialists' collaborative group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
2. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008; 26: 44-53.
3. Saloustros E, Mavroudis D, Georgoulias V,. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother. 2008; 9: 2603-2616.
4. Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene. 2001; 20: 6597-6606.
5. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003; 63: 6221-6228.
6. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003; 88: 1285-1291.
7. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 2007; 13: 7413-7420.
8. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999; 97: 575-586.
9. Quinn JE, Carser JE, James CR, et al. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol. 2009; 113: 134-142.
10. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008; 108: 289-296.
11. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010; 28: 375-379.
12. Kurebayashi J, Yamamoto Y, Kurosumi M, et al. Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res. 2006; 26: 695-701.
13. Egawa C, Miyoshi Y, Takamura Y, et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer. 2001; 95: 255-259.
14. Hayward JL, Carbone PP, Heuson JC, et al. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977; 39: 1289-1294.
15. Rodriguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010; 123: 189-196.
16. Lee LJ, Alexander B, Schnitt SJ, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers [published online ahead of print January 24, 2011]. Cancer. doi: 10.1002/cncr.25911.
17. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol. 2006; 17: 391-400.
18. Tung N, Miron A, Schnitt SJ, et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res. 2010; 12: R95.
19. Mauri D, Kamposioras K, Tsali L, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev. 2010; 36: 69-74.
20. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet. 2002; 39: 608-610.
21. Kriege M, Seynaeve C, Meijers-Heijboer H, et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009; 27: 3764-3771.
22. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009; 115: 359-363.
23. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361: 123-134.
24. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376: 235-244.